US FDA's Regulatory Flexibility To Be Tested As Delcath Overhauls Melphalan Trial Design

Accrual difficulties force changes that nullify Special Protocol Assessment; ongoing, randomized FOCUS trial in patients with ocular melanoma that has metastasized to liver will become single-arm study and target enrollment will be reduced by 66%.